According to the research report, the size of the Sepsis Diagnostics Market in the Asia Pacific is valued at USD 204.97 Million in 2021 and projected to be growing at a CAGR of 9.69% to reach USD 325.48 million by 2026.
Sepsis is a type of life-threatening organ dysfunction that arises when the body's response to an infection injures its tissues and organs. It can be caused due to weakened immune systems, chronic illness, kidney or liver disease, cancer, and severe wounds. It can be of two types of severe sepsis when there’s organ failure, and the other is a septic shock in which there are the symptoms of severe sepsis includes low blood pressure. The hospital-acquired infections and rising prevalence of sepsis have led to a growing need for its early diagnosis. The increasing incidence of the disease and its fatal effects have stimulated its growth.
Major driving forces of the market are increasing geriatric population, rising prevalence of different antibiotic-resistant bacterial strains, a growing number of surgical procedures, high incidence rates of hospital-acquired infections, and an increasing number of product approvals.
But, factors like lack of standard protocols, lack of awareness, and shortage of skilled staff are likely to hinder the growth of the market.
This research report segmented and sub-segmented the Asia Pacific Sepsis Diagnostics Market into the following categories:
The Asia Pacific sepsis diagnostics market is expected to see attractive growth over the forecast period. The major players operating in the marketplace are adopting organic growth strategies, such as product development and launch, to grow the market significantly. For example, in August 2018, a Japanese company Sysmex Corporation launched a new HISCL presepsin assay kit. This kit is designed to measure the level of presepsin, a key test parameter for bacterial sepsis. Also, the high prevalence of sepsis in key Asia Pacific countries is foreseen to drive demand for diagnostic solutions. For example, according to the 2019 report published by the PLOS Journal, India has a very high incidence of clinical sepsis. Around 17,000 births out of 100,000 were affected.
The Asia-Pacific region dominated the overall market quantitatively. The growing number of neonatal cord blood sepsis cases in India, Pakistan, and China has created significant opportunities in the Asia-Pacific sepsis diagnostic market. According to a study by Mullany, Nepal found 16%, approximately 5,212 million deaths of umbilical cord infections in five countries, which includes India, Pakistan, China, and others.
Some of the Prominent Companies leading the Asia Pacific Sepsis Diagnostics Market Profiled in the Report are bioMérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Pathogen
5.1.1 Introduction
5.1.2 Bacterial Sepsis
5.1.2.1 Gram-Negative Bacterial Sepsis
5.1.2.2 Gram-Positive Bacterial Sepsis
5.1.3 Fungal Sepsis
5.1.4 Other Pathogen Infections
5.1.5 Y-o-Y Growth Analysis, By Pathogen
5.1.6 Market Attractiveness Analysis, By Pathogen
5.1.7 Market Share Analysis, By Pathogen
5.2 Product
5.2.1 Introduction
5.2.2 Instruments
5.2.3 Blood Culture Media
5.2.4 Assay Kits & Reagents
5.2.5 Software
5.2.6 Y-o-Y Growth Analysis, By Product
5.2.7 Market Attractiveness Analysis, By Product
5.2.8 Market Share Analysis, By Product
5.3 Technology
5.3.1 Introduction
5.3.2 Microbiology
5.3.3 Molecular Diagnostics
5.3.4 Immunoassays
5.3.5 Flow Cytometry
5.3.6 Other Technologies
5.3.7 Y-o-Y Growth Analysis, By Technology
5.3.8 Market Attractiveness Analysis, By Technology
5.3.9 Market Share Analysis, By Technology
5.4 Method
5.4.1 Introduction
5.4.2 Convential Diagnostics
5.4.3 Automated Diagnostics
5.4.4 Y-o-Y Growth Analysis, By Method
5.4.5 Market Attractiveness Analysis, By Method
5.4.6 Market Share Analysis, By Method
5.5 Usability
5.5.1 Introduction
5.5.2 Laboratory Testing
5.5.3 Point-of-Care Testing
5.5.4 Y-o-Y Growth Analysis, By Usability
5.5.5 Market Attractiveness Analysis, By Usability
5.5.6 Market Share Analysis, By Usability
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Pathogen
6.1.3.3 By Product
6.1.3.4 By Technology
6.1.3.5 By Method
6.1.3.6 By Usability
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Pathogen
6.1.4.3 By Product
6.1.4.4 By Technology
6.1.4.5 By Method
6.1.4.6 By Usability
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Pathogen
6.1.5.3 By Product
6.1.5.4 By Technology
6.1.5.5 By Method
6.1.5.6 By Usability
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 bioMérieux SA
8.1.1 Overview
8.1.2 Pathogen Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 T2 Biosystem Inc
8.3 Cepheid
8.4 Thermo Fisher Scientific Inc.
8.5 Nanosphere Inc
8.6 Abbott Laboratories
8.7 Roche Diagnostics Limited
8.8 Becton, Dickinson and Company
8.9 Bruker Corporation
8.10 Beckman Coulter, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
